Business & Strategy•Aug 1, 2026•MedCity NewsVogenx IPO Raises $81M for Trial in Metabolic Disease With No Approved Drugs ↗MedCity News reports Vogenx raised $81M in its IPO to fund a clinical trial for post-bariatric hypoglycemia (PBH) with mizagliflozin, a metabolic disorder with no approved drugs.
Therapeutics Development•Jul 31, 2026•Endpoints NewsRatio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO ↗Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO
Business & Strategy•Jul 30, 2026•Fierce BiotechAttovia, Braveheart and Vogenx seek more than $500M via IPOs ↗Attovia, Braveheart and Vogenx seek more than $500M via IPOs
Business & Strategy•Jul 16, 2026•Fierce BiotechVogenx joins IPO queue to fund phase 2-stage metabolic drug ↗Vogenx joins IPO queue to fund phase 2-stage metabolic drug